Nalfurafine hydrochloride OD tablets 2.5mcg for pruritus (hemodialysis, chronic liver disease, Remitch, antipruritic)

Are Nalfurafine hydrochloride OD tablets 2.5mcg effective for pruritus (hemodialysis, chronic liver disease, Remitch, antipruritic)?

Nalfurafine Hydrochloride Tablets for the Management of Intractable Pruritus

Nalfurafine hydrochloride tablets are a prescription antipruritic medicine developed in Japan for the treatment of severe, treatment-resistant pruritus. Chronic itching, particularly uremic pruritus in patients undergoing hemodialysis, is not a minor symptom. It has a profound negative impact on sleep, emotional wellbeing, daily functioning, and has been associated with increased mortality risk. Nalfurafine tablets address this unmet clinical need through a targeted and scientifically validated mechanism.

Targeted Mechanism for Persistent Itching

Nalfurafine hydrochloride is a centrally active κ-opioid receptor (KOR) agonist derived from structural modification of the opioid antagonist naltrexone. By selectively activating the KOR pathway, nalfurafine modulates itch signaling at the central nervous system level, where conventional antihistamines and topical therapies often fail.

A clinically important feature of this medicine is its pharmacological selectivity. Unlike earlier κ-opioid receptor agonists, nalfurafine does not induce hallucinogenic or psychotomimetic effects in humans, allowing effective antipruritic action without compromising tolerability in long-term management.

Proven Effectiveness in Hemodialysis-Associated Pruritus

The clinical value of nalfurafine tablets is supported by robust evidence from large-scale studies conducted in Japan. In a randomized, placebo-controlled trial involving 337 hemodialysis patients with intractable pruritus, oral nalfurafine hydrochloride demonstrated a statistically significant reduction in itch severity compared with placebo.

According to S. Inui, “Nalfurafine hydrochloride to treat pruritus: a review”, Clinical, Cosmetic and Investigational Dermatology, 2015, Volume 8, pages 249–255, the mean decrease in the visual analog scale for pruritus reached 22 mm in the 5 μg group and 23 mm in the 2.5 μg group, compared with 13 mm in the placebo group. These results confirm meaningful symptom relief in a population where pruritus is often refractory to standard therapies.

Key Benefits of Nalfurafine Tablets

• Clinically proven reduction of severe, intractable pruritus
• Central mechanism of action addressing itch signaling beyond the skin
• High selectivity for κ-opioid receptors with no hallucinogenic effects
• Developed and extensively studied in Japan for uremic pruritus
• Suitable for patients with chronic itching unresponsive to conventional treatments

Role in Modern Pruritus Management

As a specialized pruritis medicine, nalfurafine hydrochloride tablets occupy an important role in contemporary antipruritic therapy, particularly for hemodialysis patients. Their unique mechanism differentiates them from antihistamines, corticosteroids, and topical agents, offering an option for patients whose symptoms persist despite standard care.

Patients and healthcare providers seeking to buy nalfurafine or buy antipruritic therapies with strong clinical backing often consider nalfurafine tablets for their demonstrated efficacy, tolerability, and targeted pharmacology. For individuals affected by chronic, debilitating itch, this medicine represents a scientifically grounded approach to improving quality of life and overall clinical outcomes.

Package details: 14 tablets

Dosage and administration: adults should take 1 tablet (2.5 mcg of the active ingredient) at a time, once a day after dinner or before bedtime. Yur doctor may increase the dosage according to the symptoms. However, the maximum daily dose is up to 2 tablets (5 mcg) at a time. If you are taking this medicine to relieve pruritus associated with hemodialysis, allow sufficient time after taking the medicine before starting hemodialysis. If you are taking this medicine to relieve pruritus associated with peritoneal dialysis, allow sufficient time after taking the medicine before exchanging the dialysate.

This medicine may be moistened with saliva on the tongue, gently crushed with the tongue, and swallowed together with saliva.

Active components: nalfurafine hydrochloride

Therapeutic effect: improving pruritus, only in patients who have shown an inadequate response to conventional therapies, in those undergoing hemodialysis or with chronic liver disease

Contraindications and precautions: Store in a dry cool place, out of reach of children. Do not use for pregnant or breastfeeding women. This medicine may cause drowsiness or lightheadedness. Avoid operating hazardous machinery, including driving a vehicle. Do not consume grapefruit juice, as it may enhance the effects of the medicine. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.